Characteristics of Adverse Events Following Immunization Reporting in Children: The Japanese Adverse Drug Event Report Database
| Autor: | Gen Oyanagi, Nariyasu Mano, Takamasa Sakai, Aoi Noda, Taku Obara, Masami Tsuchiya |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Haemophilus influenzae type
Immunology lcsh:Medicine adverse events following immunization computer.software_genre 030226 pharmacology & pharmacy Article 03 medical and health sciences 0302 clinical medicine children Conjugate vaccine vaccine Drug Discovery Pharmacovigilance Medicine Pharmacology (medical) 030212 general & internal medicine Adverse effect Pharmacology Database business.industry spontaneous reports lcsh:R Vaccination Infectious Diseases Immunization Adverse drug event business computer |
| Zdroj: | Vaccines, Vol 8, Iss 357, p 357 (2020) Vaccines Volume 8 Issue 3 |
| Popis: | The present study aimed to describe the trends and characteristics of adverse events following immunization (AEFI) reporting for children in the Japanese Adverse Drug Event Report database (JADER). We used 6280 AEFI reports for children aged < 19 years among 504,407 ADR reports included in the JADER from 2004 to 2017. The number of AEFI reports gradually increased among children aged < 10 years and was the highest in 2011 among children aged 10-19 years. The number of suspected vaccines per AEFI report increased after 2011 among children aged < 10 years. The percentage of &ldquo death&rdquo and &ldquo did not recover&rdquo as AEFI outcomes reported were 4.3% and 3.7% among children aged < 10 years and 0.2% and 21.1% among children aged 10&ndash 19 years, respectively. The most frequently reported vaccine&ndash reaction pair was Haemophilus influenzae type b conjugate vaccine and pyrexia among children aged < 10 years and recombinant adsorbed bivalent human papillomavirus-like particle vaccine and a loss of consciousness among children aged 10-19 years. It is necessary to consider the Weber effects to understand the trend and characteristics of AEFI reporting because pharmacovigilance activity regarding vaccination is not sufficient in Japan. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|